Real world experience on treatment, outcome and toxicity of crizotinib in patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer.

Conclusions: This retrospective analysis of a real-world experience confirms the therapeutic benefit of crizotinib in advanced ALK-positive NSCLC. Our data showed crizotinib is tolerable and effective, comparable with literature report. Occasional serious cardiac toxicity requires attention. PMID: 31656659 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/31656659?dopt=Abstract

Source: Journal of Thoracic Disease - October 30, 2019 Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research